Pharma BD Deal Intelligence
Gilead to acquire YM BioSciences for ~$510 million, gaining CYT387, a once-daily selective JAK1/JAK2 inhibitor with positive Phase 1/2 myelofibrosis data,…
Gilead paid $510M for momelotinib via YM BioSciences and divested it for just $3M upfront after Phase 3 trials underwhelmed, illustrating one of Gilead's…
Momelotinib is profiled as one of pharma's biggest dropped-drug comebacks: Gilead paid $510M to acquire YM BioSciences, abandoned the asset, then watched…
Source summaries from our enrichment pipeline; follow links for originals.
All 13 sources with sentiment breakdown →
Gilead tender offer at C$2.95/share cash (~$510M) for YM BioSciences. Acquired CYT387 (momelotinib), JAK1/JAK2 inhibitor for myelofibrosis with positive Phase 1/2 data in 166 patients. Phase 3 planned for H2 2013.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Gilead Sciences Inc. / YM BioSciences Inc. (this deal) | 2012 | $510M | 17 |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Gilead Sciences Inc. / Triangle Pharmaceuticals Inc. | 2002 | $464M | 96 |
| Gilead Sciences Inc. / CymaBay Therapeutics | 2024 | $4.4B | 76 |
| Gilead Sciences Inc. / Nurix Therapeutics Inc. | 2019 | $2.3B | 69 |
| Gilead Sciences Inc. / Immunomedics Inc. | 2020 | $21.0B | 68 |
| Gilead Sciences Inc. / Kite Pharma, Inc. | 2017 | $11.9B | 67 |
← Browse all deals · How we score deals
More: 2012 deals · Gilead Sciences Inc. deals · Hematology deals